European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): HBVaxPro, hepatitis B vaccine (recombinant DNA), Date of authorisation: 27/04/2001, Revision: 35, Status: Authorised

Submitted by Anonymous (not verified) on 7 November 2025 - 15:00

Human medicines European public assessment report (EPAR): HBVaxPro, hepatitis B vaccine (recombinant DNA), Date of authorisation: 27/04/2001, Revision: 35, Status: Authorised

Clinical Trial Information System (CTIS) structured data form - Initial application, additional Member State Concerned, (Multi trial) substantial modification, non-substantial modification, and Request for information (RFI)

Submitted by Anonymous (not verified) on 7 November 2025 - 14:51

Clinical Trial Information System (CTIS) structured data form - Initial application, additional Member State Concerned, (Multi trial) substantial modification, non-substantial modification, and Request for information (RFI)

Human medicines European public assessment report (EPAR): Baiama, aflibercept, Date of authorisation: 13/01/2025, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 7 November 2025 - 14:51

Human medicines European public assessment report (EPAR): Baiama, aflibercept, Date of authorisation: 13/01/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 7 November 2025 - 14:45

Human medicines European public assessment report (EPAR): Ahzantive, aflibercept, Date of authorisation: 13/01/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Date of authorisation: 22/07/2014, Revision: 19, Status: Authorised

Submitted by Anonymous (not verified) on 7 November 2025 - 14:18

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Date of authorisation: 22/07/2014, Revision: 19, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Vaxxinact H5, Avian influenza virus, subtype H5, haemagglutinin (recombinant), Status: Opinion

Submitted by Anonymous (not verified) on 7 November 2025 - 14:00

Veterinary medicines European public assessment report (EPAR): Vaxxinact H5, Avian influenza virus, subtype H5, haemagglutinin (recombinant), Status: Opinion

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness